Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Mult Scler
; 27(11): 1803-1805, 2021 10.
Article
en En
| MEDLINE
| ID: mdl-33666121
ABSTRACT
BACKGROUND:
Hemophagocytic lymphohistiocytosis (HLH) is a rarely recognized hyperinflammatory condition of high death risk.OBJECTIVE:
The objective was to describe a case of HLH in a patient with multiple sclerosis (MS) treated with ocrelizumab.METHODS:
Clinical observation, laboratory testing, and use of HLH-2004 criteria for HLH diagnosis.RESULTS:
A 32-year-old Caucasian female developed HLH during ocrelizumab treatment. She met six of the eight HLH criteria including fever, splenomegaly, cytopenia, hypertriglyceridemia and hypofibrinogenemia, high serum ferritin level, and low natural killer (NK) cells.CONCLUSION:
HLH should be considered in the differential diagnosis in MS patients displaying a fever and malaise syndrome following administration of ocrelizumab.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hipertrigliceridemia
/
Linfohistiocitosis Hemofagocítica
/
Esclerosis Múltiple
Tipo de estudio:
Diagnostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Mult Scler
Asunto de la revista:
NEUROLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Polonia